Pressemelding -

PRESS RELEASE: Calanus As invests in a new production facility

The decision has been triggered by the Government's decision to open for commercial harvesting of Calanus finmarchicus and the increasing demand for the company's products.

Tromsø, Norway, June 4, 2019.

Calanus AS is a Norwegian biomarine company pioneering harvesting and utilization of the copepod Calanus finmarchicus. The company has developed the entire value chain for sustainable harvesting and biorefining of the hitherto unused resource C. finmarchicus, which is Norway's largest renewable and harvestable marine resource. Calanus AS manufactures unique health and nutrition products that are for sale or under launch in several countries. Based on the Government's decision to open for commercial harvesting of C. finmarchicus, and increasing demand for the company's products, Calanus AS has now decided to build the first full-scale industrial pilot plant for biorefining of C. finmarchicus. The plant will be located above the Arctic circle, in Sortland in northern Norway.

CEO Gunnar Rørstad in Calanus AS states: “We are pleased that the Ministry of Trade, Industry and Fisheries has decided to open for commercial harvesting of Calanus finmarchicus. Calanus AS has developed extensive knowledge on the harvesting of the resource and its products - as well as the market opportunities for this exciting raw material. The market potential for our unique health and nutrition products has been confirmed, both through strong customer growth in Norway and considerable international interest. To be able to serve existing and future customers, it is absolutely necessary to increase our production capacity.”.

The factory project has a total investment budget of EUR 18 million, of which EUR 7 million is to be financed with equity.

The company's main product is Calanus® Oil, an ecologically responsible and sustainable source of omega-3 fatty acids for humans. Calanus® Oil has a unique composition and has shown beneficial properties such as improved insulin sensitivity, reduction of intra-abdominal obesity and strong anti-inflammatory effects. Calanus As is now working on further development of clinical documentation in humans in several countries with an aim to apply for approval of health claims in accordance with EU and other Authorities' regulation. The company also works with functional ingredients aimed at both human and animal applications, including the global aquaculture industry.

For more information, contact CEO Gunnar Rørstad on phone +47 913 65 942 or e-mail: gunnar.rorstad@calanus.no, or visit the Calanus website www.calanus.com. 

Related links

Emner

Calanus As is a biomarine company pioneering harvesting and utilization of the crustacean Calanus finmarchicus, and is well positioned to play a key role in industrialization of the entire value chain for through its intellectual property rights. Calanus As develops functional health- and nutrition ingredients for humans and animals exclusively from this valuable raw material. The Company’s main product is Calanus® Oil, an ecologically sustainable source of omega-3 fatty acids for humans. Calanus® Oil has unique composition and has shown benefits like improved insulin sensitivity, reduced deposition of intra-abdominal fat and powerful anti-inflammatory effects.

Kontakter

Snorre Angell

Snorre Angell

Pressekontakt CEO +4791349671

Relatert media

  • Fabrikkskisse
  • Lisens: Bruk i media
    Innholdet kan lastes ned, bli brukt og delt i ulike medier av for eksempel journalister, bloggere, spaltister, kommentatorer etc., med den hensikt å formidle, fortelle og kommentere dine pressemeldinger, oppslag eller informasjon, forutsatt at innholdet er uendret og brukt i sin helhet. Opphaver skal navngis i den grad og på den måten god skikk tilsier (dette betyr f.eks. at fotografer nesten alltid skal navngis).
Last ned
  • Gunnar Rorstad
  • Lisens: Bruk i media
    Innholdet kan lastes ned, bli brukt og delt i ulike medier av for eksempel journalister, bloggere, spaltister, kommentatorer etc., med den hensikt å formidle, fortelle og kommentere dine pressemeldinger, oppslag eller informasjon, forutsatt at innholdet er uendret og brukt i sin helhet. Opphaver skal navngis i den grad og på den måten god skikk tilsier (dette betyr f.eks. at fotografer nesten alltid skal navngis).
Last ned
  • CALANUS-med copyright
  • Lisens: Bruk i media
    Innholdet kan lastes ned, bli brukt og delt i ulike medier av for eksempel journalister, bloggere, spaltister, kommentatorer etc., med den hensikt å formidle, fortelle og kommentere dine pressemeldinger, oppslag eller informasjon, forutsatt at innholdet er uendret og brukt i sin helhet. Opphaver skal navngis i den grad og på den måten god skikk tilsier (dette betyr f.eks. at fotografer nesten alltid skal navngis).
Last ned
  • CalanusOil-eske-forside
  • Lisens: Bruk i media
    Innholdet kan lastes ned, bli brukt og delt i ulike medier av for eksempel journalister, bloggere, spaltister, kommentatorer etc., med den hensikt å formidle, fortelle og kommentere dine pressemeldinger, oppslag eller informasjon, forutsatt at innholdet er uendret og brukt i sin helhet. Opphaver skal navngis i den grad og på den måten god skikk tilsier (dette betyr f.eks. at fotografer nesten alltid skal navngis).
Last ned
  • Prod1
  • Lisens: Bruk i media
    Innholdet kan lastes ned, bli brukt og delt i ulike medier av for eksempel journalister, bloggere, spaltister, kommentatorer etc., med den hensikt å formidle, fortelle og kommentere dine pressemeldinger, oppslag eller informasjon, forutsatt at innholdet er uendret og brukt i sin helhet. Opphaver skal navngis i den grad og på den måten god skikk tilsier (dette betyr f.eks. at fotografer nesten alltid skal navngis).
Last ned

Relatert innhold

PRESS RELEASE: Norway opens for commercial harvesting of zooplankton

Tromsø, Norway, April 1st 2019.
The Norwegian Government has decided to open for commercial harvesting of Calanus finmarchicus, the small copepod that constitutes the largest renewable and harvestable resource in the Norwegian sea.
Based on a precautionary approach, the quota has initially been set at 254 000 tons per year, which is significantly lower than the potential sustainable yield.<

Calanus® Oil approved by Health Canada

Health Canada´s Natural and Non-prescription Health Products Directorate (NNHPD) has approved Calanus® Oil as a Natural Health Product.

A new clinical trial shows that daily intake of Calanus® Oil improves cardiac function and insulin sensitivity

​In a recent study, a research team from The Academy of science at Charles University and the Czech Republic University Hospital Kralovske Vinohrady in Prague has obtained exciting results on heart function and insulin sensitivity in senior women combining physical exercise with Calanus® Oil supplementation.

Norway files application to include Calanus Oil in Codex Alimentarius

Norwegian Authorities, represented by the Norwegian Food Safety Authority, have submitted an application to the Codex Alimentarius Commission to include calanus oil in the Codex Standard (CODEX STAN 329-2017). Codex Alimentarius is a joint initiative from The Food and Agriculture Organization and World Health Organization, both organizations from the United Nations.
Oil from Calanus finmarchicu

PRESS RELEASE: First Review Article on Health Effects of Wax Ester Omega-3s

A recent review article by Schots et al., published in Frontiers in Pharmacology, investigates how the different constituents of Calanus® Oil can contribute to the prevention of obesity-induced low-grade inflammation and the associated metabolic disturbances. Calanus® Oil is a natural oil derived from the 1-year copepod Calanus finmarchicus. In addition to having the unique wax ester form, Calanus

PRESS RELEASE: A new study shows that Calanus® Oil intake antagonizes negative changes in gut microbiota due to obesity

A new preclinical study conducted by a research team from Uit- The Arctic University of Norway, shows that Calanus® Oil supplementation in obese mice prevents negative changes in microbiota. This has led to new theories about the mechanisms of action of Calanus® Oil.
Current evidence suggests that obesity and its comorbidities are intrinsically linked with unfavorable changes in the intestinal

Calanus AS certified by Friend of the Sea®

Tromsø, Norway, December 11, 2020

Friend of the Sea®, one of the leading global certification standards for products and services that respect and protect the marine environment, has certified Calanus AS for harvesting of the zooplankton Calanus finmarchicus and the products derived from this huge marine resource. Calanus AS can now display the Friend of the Sea® eco-friendly label on their

- Godt for deg. Godt for planeten.

Zooca® (Calanus AS) er et biomarint industriselskap som leder an i utvikling, fremstilling og salg av unike helse- og ernæringsprodukter basert på bærekraftig utnyttelse av det marine zooplanktonet raudåte (Calanus finmarchicus), en av de største fornybare marine ressursene globalt. Zooca® har gjennomført forskning og utviklingsarbeid innenfor høstingsteknologi, prosess- og applikasjonsutvikling, produktutvikling og dokumentasjon for kommersialisering. De primære forretningsområdene er ernærings- og helseprodukter til mennesker og dyr innenfor områdene kosttilskudd, funksjonelle ingredienser til oppdrett av marin fisk og reker, samt laksefisk og som ingredienser i pet food.

Hovedproduktene er Zooca® Calanus® Oil, som benyttes som høyverdig kosttilskudd hos mennesker, og Zooca® Hydrolysate, som benyttes funksjonell ingrediens i dyrefôr og startfôr innenfor oppdrett. Selskapet er den eneste bedriften i Norge som driver industriell utnyttelse av zooplankton.

Zooca (Calanus AS)
Stortorget 1, 5. etasje, Kystens hus
9008 TROMSØ
Norge
Zooca® - The Calanus® Company